Multicenter, open-label, randomized study in patients with ovarian cancer

Trial Profile

Multicenter, open-label, randomized study in patients with ovarian cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Nivolumab (Primary) ; Doxorubicin; Gemcitabine
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 22 May 2017 Planned number of patients changed from 116 to 300.
    • 22 May 2017 Planned End Date changed from 1 May 2019 to 1 Jul 2020.
    • 22 May 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top